DPP4 and diabetes mellitus: In the clinical perspectives of DPP4 inhibitors in the prevention and treatment of HCC, a nationwide study in Taiwan demonstrated that DPP4 inhibitors decreased the risk of HCC in patients with chronic hepatitis C and type 2 diabetes mellitus [51].